17 July 2023
Oxford Cannabinoid Technologies Holdings plc
PDMR and Director Dealings
Oxford Cannabinoid Technologies Holdings plc ("the Company"), announces that it has been informed today that Clarissa Sowemimo-Coker, Chief Executive Officer and Robin Bennett, General Counsel and Company Secretary have today purchased ordinary shares of £0.01 in the Company ("Ordinary Shares").
| Director/PDMR | Total number of Ordinary Shares purchased | Price per Ordinary Share | Number of Ordinary Shares held following the purchase |
| Clarissa Sowemimo-Coker
| 310,406
| £0.009064
| 1,500,000
|
| Robin Bennett
| 331,012
| £0.009
| 331,012
|
The PDMR forms are set out below.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018).
The Directors of the Company accept responsibility for the content of this announcement.
Enquiries:
| Oxford Cannabinoid Technologies Holdings plc Clarissa Sowemimo-Coker (CEO)
| +44 (0)20 3034 2820 clarissa@oxcantech.com
|
| Cairn Financial Advisers LLP Emily Staples Jo Turner
|
+44 (0)20 7213 0897 +44 (0) 20 7213 0885 |
| Axis Capital Markets Limited Richard Hutchison
Walbrook PR Limited Paul Vann/Nick Rome/Joe Walker
|
+44 (0)20 3026 0320
+44 (0)20 7933 8780 +44 (0)7768 807631
|
About Oxford Cannabinoid Technologies Holdings Plc:
Oxford Cannabinoid Technologies Holdings plc ("OCTP") is the holding company of Oxford Cannabinoid Technologies Ltd (together the "Group"), a pharmaceutical Group developing prescription cannabinoid medicines targeting the U$ multi-billion global pain market.
OCTP currently has a portfolio of four drug development programmes. Its lead compound, OCT461201, will initially target neuropathic and visceral pain (including irritable bowel syndrome ("IBS") and chemotherapy induced peripheral neuropathy ("CIPN")), with the Phase I clinical trial, aimed at demonstrating safety and tolerability. Trial results are expected in Q3 2023. The global market for CIPN alone is currently valued at US$1.61bn and is forecast to reach US$2.37bn by the year 2027.
OCTP's drug development pipeline comprises both natural and synthetic compounds, and includes compounds targeting trigeminal neuralgia, a severe type of face pain, and cannabinoid derivatives targeting pain and potentially other therapeutic areas. Having established an exclusive license agreement with Canopy Growth Corporation for their entire pharmaceutical cannabinoid derivative library, OCTP now has a portfolio of almost five hundred derivatives and intellectual property rights including fourteen patent families and associated research data.
OCTP has a clearly defined path to commercialisation, revenues and growth. The Group is developing drug candidates through clinical trials to gain regulatory approval (FDA/MHRA/EMA) that will enable medical professionals to prescribe them with confidence. OCTP's portfolio aims to balance risk, value and time to market, whilst ensuring market exclusivity around all its key activities.
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | ||||||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||||
| a. | Name | Clarissa Sowemimo-Coker | ||||||
| 2 | Reason for notification |
| ||||||
| a. | Position/Status | Chief Executive Officer | ||||||
| b. | Initial notification/ Amendment | Initial notification | ||||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
| a. | Name | Oxford Cannabinoid Technologies Holdings plc | ||||||
| b. | LEI |
2138005SRWT4998BCE35
| ||||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
| a. | Description of the financial instrument, type of instrument |
Ordinary shares of £0.01 each
GB00BMVMRB86 | ||||||
| b. | Nature of the transaction | Acquisition of ordinary shares of £0.01 each | ||||||
| c. | Price(s) and volume(s) | | | | | | ||
| | Price(s) | Volume(s) | | |||||
| £0.009064 | 310,406 | | ||||||
| | ||||||||
| d. | Aggregated information
- Aggregated Volume
- Price | N/A - single transaction
| ||||||
| e. | Date of the transaction | 17 July 2023 | ||||||
| f. | Place of the transaction | London, UK | ||||||
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | ||||||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||||
| a. | Name | Robin Bennett | ||||||
| 2 | Reason for notification |
| ||||||
| a. | Position/Status | General Counsel and Company Secretary | ||||||
| b. | Initial notification/ Amendment | Initial notification | ||||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
| a. | Name | Oxford Cannabinoid Technologies Holdings plc | ||||||
| b. | LEI |
2138005SRWT4998BCE35
| ||||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
| a. | Description of the financial instrument, type of instrument |
Ordinary shares of £0.01 each
GB00BMVMRB86 | ||||||
| b. | Nature of the transaction | Acquisition of ordinary shares of £0.01 each | ||||||
| c. | Price(s) and volume(s) | | | | | | ||
| | Price(s) | Volume(s) | | |||||
| £0.009 | 331,012 | | ||||||
| | | | | |||||
| | ||||||||
| d. | Aggregated information
- Aggregated Volume
- Price | N/A - single transaction
| ||||||
| e. | Date of the transaction | 17 July 2023 | ||||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.